论文部分内容阅读
目的：探讨子宫内膜癌中抗凋亡基因Ｂｃｌ－２和细胞增殖活性指标ｋｉ－６７的表达及其与临床病理因素和预后的关系。方法：采用ＳＰ法免疫组化染色石蜡包埋的子宫内膜癌组织。结果：６１例子宫内膜癌中组织学分级Ⅰ级者较Ⅱ、Ⅲ级子宫内膜癌Ｂｃｌ－２表达显著升高（ Ｐ＜ ０．０１），存活时间超过５年者较５年内死亡者的表达明显增加（Ｐ＜０．０５）。而各临床分期间，合并宫内膜增生与未合并宫内膜增生者间Ｂｃｌ－２表达无明显差异（ Ｐ＞ ０．０５）。６１例子宫内膜癌以单克隆抗体ＭＩＢ－１代表的细胞增殖指数与组织学分级、临床分期均无关。但５年内死亡病例组的平均增殖指数明显高于存活时间超过５年者（Ｐ＜ ０．０１）。Ｂｃｌ－２与ＭＩＢ－１在子宫内膜癌中的表达没有明显的相关性（Ｐ ＞ ０．０１）。结论：Ｂｃｌ－２在从子宫内膜增生、非典型增生到癌的变化过程中逐渐减少，是一个重要的预后因素。ｋｉ－６７亦表现出独立的预后特点
Objective: To investigate the expression of Bcl-2 and ki-67, an inhibitor of apoptosis in endometrial carcinoma, and its relationship with clinicopathological factors and prognosis. Methods: SP immunohistochemical staining of paraffin-embedded endometrial cancer tissue. Results: The expression of Bcl-2 in 61 cases of endometrial carcinoma with histological grade Ⅰ was significantly higher than that of Ⅱ and Ⅲ endometrial carcinoma (P <0.01), and those with more than 5 years of survival were lower than those with 5 years of death The expression was significantly increased (P <0.05). There was no significant difference in the expression of Bcl-2 between the patients with endometrial hyperplasia and those without endometrial hyperplasia during each clinical stage (P> 0.05). 61 cases of endometrial cancer with monoclonal antibody MIB-1 represents the cell proliferation index and histological grade, clinical stage have nothing to do. However, the mean proliferative index of the death cases in 5 years was significantly higher than that of those who survived for more than 5 years (P <0.01). There was no significant correlation between the expression of Bcl-2 and MIB-1 in endometrial carcinoma (P> 0.01). Conclusion: Bcl-2 is gradually decreased from endometrial hyperplasia and atypical hyperplasia to carcinogenesis, which is an important prognostic factor. ki-67 also showed independent prognostic features